216 related articles for article (PubMed ID: 29348495)
1. Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells.
Augello G; Modica M; Azzolina A; Puleio R; Cassata G; Emma MR; Di Sano C; Cusimano A; Montalto G; Cervello M
Cell Death Dis; 2018 Jan; 9(2):28. PubMed ID: 29348495
[TBL] [Abstract][Full Text] [Related]
2. The evaluation of the anti-cancer activity of ixazomib on Caco2 colon solid tumor cells, comparison with bortezomib.
Engür S; Dikmen M
Acta Clin Belg; 2017 Dec; 72(6):391-398. PubMed ID: 28327055
[TBL] [Abstract][Full Text] [Related]
3. The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs.
Paulus A; Masood A; Miller KC; Khan AN; Akhtar D; Advani P; Foran J; Rivera C; Roy V; Colon-Otero G; Chitta K; Chanan-Khan A
Br J Haematol; 2014 Apr; 165(1):78-88. PubMed ID: 24467634
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
Chauhan D; Tian Z; Zhou B; Kuhn D; Orlowski R; Raje N; Richardson P; Anderson KC
Clin Cancer Res; 2011 Aug; 17(16):5311-21. PubMed ID: 21724551
[TBL] [Abstract][Full Text] [Related]
5. MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinical models.
Gu JJ; Hernandez-Ilizaliturri FJ; Mavis C; Czuczman NM; Deeb G; Gibbs J; Skitzki JJ; Patil R; Czuczman MS
Anticancer Drugs; 2013 Nov; 24(10):1030-8. PubMed ID: 23995855
[TBL] [Abstract][Full Text] [Related]
6. The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma.
Suarez-Kelly LP; Kemper GM; Duggan MC; Stiff A; Noel TC; Markowitz J; Luedke EA; Yildiz VO; Yu L; Jaime-Ramirez AC; Karpa V; Zhang X; Carson WE
Oncotarget; 2016 Dec; 7(49):81172-81186. PubMed ID: 27783987
[TBL] [Abstract][Full Text] [Related]
7. Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease.
Garcia-Gomez A; Quwaider D; Canavese M; Ocio EM; Tian Z; Blanco JF; Berger AJ; Ortiz-de-Solorzano C; Hernández-Iglesias T; Martens AC; Groen RW; Mateo-Urdiales J; Fraile S; Galarraga M; Chauhan D; San Miguel JF; Raje N; Garayoa M
Clin Cancer Res; 2014 Mar; 20(6):1542-54. PubMed ID: 24486586
[TBL] [Abstract][Full Text] [Related]
8. Comparison of antiproliferative and apoptotic effects of a novel proteasome inhibitor MLN2238 with bortezomib on K562 chronic myeloid leukemia cells.
Engür S; Dikmen M; Öztürk Y
Immunopharmacol Immunotoxicol; 2016; 38(2):87-97. PubMed ID: 26667773
[TBL] [Abstract][Full Text] [Related]
9. KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism.
Chattopadhyay N; Berger AJ; Koenig E; Bannerman B; Garnsey J; Bernard H; Hales P; Maldonado Lopez A; Yang Y; Donelan J; Jordan K; Tirrell S; Stringer B; Xia C; Hather G; Galvin K; Manfredi M; Rhodes N; Amidon B
PLoS One; 2015; 10(12):e0144825. PubMed ID: 26709701
[TBL] [Abstract][Full Text] [Related]
10. MLN2238 synergizes BH3 mimetic ABT-263 in castration-resistant prostate cancer cells by induction of NOXA.
Wei X; Zhou P; Lin X; Lin Y; Wu S; Diao P; Xie H; Xie K; Tang P
Tumour Biol; 2014 Oct; 35(10):10213-21. PubMed ID: 25027405
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies.
Lee EC; Fitzgerald M; Bannerman B; Donelan J; Bano K; Terkelsen J; Bradley DP; Subakan O; Silva MD; Liu R; Pickard M; Li Z; Tayber O; Li P; Hales P; Carsillo M; Neppalli VT; Berger AJ; Kupperman E; Manfredi M; Bolen JB; Van Ness B; Janz S
Clin Cancer Res; 2011 Dec; 17(23):7313-23. PubMed ID: 21903769
[TBL] [Abstract][Full Text] [Related]
12. The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.
Richardson PG; Moreau P; Laubach JP; Gupta N; Hui AM; Anderson KC; San Miguel JF; Kumar S
Future Oncol; 2015; 11(8):1153-68. PubMed ID: 25832873
[TBL] [Abstract][Full Text] [Related]
13. Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma.
Augello G; Emma MR; Cusimano A; Azzolina A; Mongiovì S; Puleio R; Cassata G; Gulino A; Belmonte B; Gramignoli R; Strom SC; McCubrey JA; Montalto G; Cervello M
Int J Cancer; 2019 May; 144(10):2613-2624. PubMed ID: 30488605
[TBL] [Abstract][Full Text] [Related]
14. Simvastatin-induced cell cycle arrest through inhibition of STAT3/SKP2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells.
Wang ST; Ho HJ; Lin JT; Shieh JJ; Wu CY
Cell Death Dis; 2017 Feb; 8(2):e2626. PubMed ID: 28230855
[TBL] [Abstract][Full Text] [Related]
15. Spotlight on ixazomib: potential in the treatment of multiple myeloma.
Muz B; Ghazarian RN; Ou M; Luderer MJ; Kusdono HD; Azab AK
Drug Des Devel Ther; 2016; 10():217-26. PubMed ID: 26811670
[TBL] [Abstract][Full Text] [Related]
16. Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma.
Ravi D; Beheshti A; Abermil N; Passero F; Sharma J; Coyle M; Kritharis A; Kandela I; Hlatky L; Sitkovsky MV; Mazar A; Gartenhaus RB; Evens AM
Cancer Res; 2016 Jun; 76(11):3319-31. PubMed ID: 26988986
[TBL] [Abstract][Full Text] [Related]
17. Post-Transplantation Cyclophosphamide and Ixazomib Combination Rescues Mice Subjected to Experimental Graft-versus-Host Disease and Is Superior to Either Agent Alone.
Al-Homsi AS; Goodyke A; McLane M; Abdel-Mageed S; Cole K; Muilenburg M; Feng Y
Biol Blood Marrow Transplant; 2017 Feb; 23(2):255-261. PubMed ID: 27888016
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B Virus X Protein (HBx) Is Responsible for Resistance to Targeted Therapies in Hepatocellular Carcinoma: Ex Vivo Culture Evidence.
Huang P; Zhuang B; Zhang H; Yan H; Xiao Z; Li W; Zhang J; Tang Q; Hu K; Koeffler HP; Wang J; Yin D
Clin Cancer Res; 2015 Oct; 21(19):4420-30. PubMed ID: 26059188
[TBL] [Abstract][Full Text] [Related]
19. Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma.
Vandewynckel YP; Coucke C; Laukens D; Devisscher L; Paridaens A; Bogaerts E; Vandierendonck A; Raevens S; Verhelst X; Van Steenkiste C; Libbrecht L; Geerts A; Van Vlierberghe H
Oncotarget; 2016 Jun; 7(23):34988-5000. PubMed ID: 27167000
[TBL] [Abstract][Full Text] [Related]
20. Ixazomib - the first oral proteasome inhibitor.
Xie J; Wan N; Liang Z; Zhang T; Jiang J
Leuk Lymphoma; 2019 Mar; 60(3):610-618. PubMed ID: 30614337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
